Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PALO ALTO NETWORKS, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · third_quarter · Q3
General Issues related to AI
general issues related to Cyber security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUE GENES, LLC via
Source: Senate LDA
2026 · third_quarter · Q3
Issues related to the America First Global Health Strategy, bilateral global health cooperation, and potential third-party clinical services support for U.S. global health assistance and partner-country health initiatives.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PALO ALTO NETWORKS, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · second_quarter · Q2
General Issues related to AI
general issues related to Cyber security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUE GENES, LLC via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · second_quarter · Q2
Issues related to coverage of pharmacogenomics under TRICARE, Medicare and Veterans Health Administration
Issues related to the America First Global Health Strategy, bilateral global health cooperation, and potential third-party clinical services support for U.S. global health assistance and partner-country health initiatives.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PALO ALTO NETWORKS, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · first_quarter · Q1
General Issues related to AI
general issues related to Cyber security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUE GENES, LLC via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · first_quarter · Q1
Issues related to coverage of pharmacogenomics under TRICARE, Medicare and Veterans Health Administration
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PALO ALTO NETWORKS, INC. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · fourth_quarter · Q4
general issues related to Cyber security
General Issues related to AI
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUE GENES, LLC via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · fourth_quarter · Q4
Issues related to coverage of pharmacogenomics under TRICARE, Medicare and Veterans Health Administration
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PALO ALTO NETWORKS, INC. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · third_quarter · Q3
general issues related to Cyber security
General Issues related to AI
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PALO ALTO NETWORKS, INC. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · second_quarter · Q2
general issues related to Cyber security
General Issues related to AI
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PALO ALTO NETWORKS, INC. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · first_quarter · Q1
general issues related to Cyber security
General Issues related to AI
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PALO ALTO NETWORKS, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2024 · fourth_quarter · Q4
general issues related to cyber security issues
general issuesrelated to AI
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PALO ALTO NETWORKS, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2024 · third_quarter · Q3
general issuesrelated to AI
general issues related to cyber security issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PALO ALTO NETWORKS, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2024 · second_quarter · Q2
general issuesrelated to AI
general issues related to cyber security issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PALO ALTO NETWORKS, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2024 · first_quarter · Q1
general issues related to cyber security issues
general issuesrelated to AI
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PALO ALTO NETWORKS, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2024 · first_quarter · RR
General issues related to HOM and SCI
General issues related to HOM and SCI